Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given his Buy rating due to a combination of factors related to Trevi Therapeutics’ recent developments and future potential. The company is set to present data from its Haduvio Phase 2a RIVER trial in RCC at the upcoming ERS 2025, which is expected to provide incremental updates on the efficacy and safety of nalbuphine ER. This includes showcasing its antitussive benefits and patient-reported outcomes, which have already been detailed in previous reports.
Moreover, Trevi Therapeutics is exploring a significant market expansion opportunity by integrating non-IPF ILD development with its existing IPF program. This strategic move could leverage cost synergies and potentially accelerate market entry if the FDA approves parallel Phase 3 trials for both conditions. The anticipated regulatory update and clarity on Haduvio’s market timeline are expected to be exciting for investors, reinforcing the Buy rating ahead of these developments.
Chatterjee covers the Healthcare sector, focusing on stocks such as Opus Genetics, Theravance Biopharma, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 36.8% and a 77.50% success rate on recommended stocks.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $21.00 price target.